This Article Full Text Full Text (PDF) eLetters: Submit a response to this article Purchase Article View Shopping Cart Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services E-mail this article link to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Reprints/Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Wadler, S. Articles by Schwartz, E. L. Search for Related Content PubMed PubMed Citation Articles by Wadler, S. Articles by Schwartz, E. L.

New Advances in Interferon Therapy of Cancer

Department of Oncology, Montefiore Medical Center and the Albert Einstein Cancer Center, Bronx, New York, USA

Correspondence: Scott Wadler, M.D., Department of Oncology, Hofheimer One, Montefiore Medical Center, 111 East 210th Street, Bronx, New York 10467, USA. Telephone: 718-920-4830; Fax: 718-798-7474.

Substantial increases in both the understanding of the cellular mechanisms of actions of interferon (IFN) and in its clinical use in cancer have occurred in recent years. The efficacy of interferon for the treatment of select malignancies has been established, and IFN- and IFN-ß have been approved by the Food and Drug Administration for multiple clinical indications. IFN- increased median survival and relapse-free survival in patients with locally advanced melanoma when used as adjuvant therapy and had modest activity against advanced disease. In other tumors where studies indicated that IFN lacked direct therapeutic activity, clinical trials suggested that it increased the antitumor activity of cytotoxic chemotherapeutic agents when used in combination therapy. IFN has substantial activity in chronic myelogenous leukemia, increasing survival in patients in early chronic phase when compared with conventional chemotherapy, and has some activity in non-Hodgkin’s lymphoma in combination with cytotoxic agents. Recent molecular and pharmacologic studies defining cellular receptor activation, signal transduction pathways, and biochemical modulating activities of interferon have yet to be fully incorporated into clinical development. Further preclinical advances along with the expanding identification of potentially clinically sensitive tumors make it likely that the use of IFN in cancer chemotherapy will continue to grow.

Key Words. Interferons • Interferon receptors • Neoplasms • Antineoplastic biotherapy • Antiangiogenesis • Melanoma • Renal cell carcinoma • Non-Hodgkin’s lymphoma • Multiple myeloma • Chronic myelogenous leukemia

This article has been cited by other articles:

				J. Lechner, N. Malloth, T. Seppi, B. Beer, P. Jennings, and W. Pfaller IFN-{alpha} induces barrier destabilization and apoptosis in renal proximal tubular epithelium Am J Physiol Cell Physiol, January 1, 2008; 294(1): C153 - C160. [Abstract] [Full Text] [PDF]